• Anida Pharma Inc., of Cambridge, Mass., said it was awarded funding from the Michael J. Fox Foundation for Parkinson’s Research to conduct preclinical research using its lead compound for neurodegenerative diseases, Neuroprotectin D1, an endogenous DHA-derived lipid mediator that regulates circuits of resolution.